The Infrastructure Play Hiding in Plain Sight Across Cardiac Care

🔗 원문 전체 보기 → Financial Post

요약

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) — Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven’t noticed yet…

본문

This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content

Issued on behalf of VentriPoint Diagnostics Ltd.

Sign In or Create an Account

or View more offersArticle content

VANCOUVER, British Columbia, April 16, 2026 (GLOBE NEWSWIRE) — Equity-Insider.com News Commentary – The American heart care market is undergoing a structural shift that most retail investors haven’t noticed yet. The U.S. cardiovascular devices sector is on track to nearly double, from $22.08 billion in 2025 to $41.29 billion by 2032, fueled by aging demographics and a wave of next-generation diagnostic platforms[1]. At the same time, 75% of U.S. health systems are now rolling out AI-powered clinical tools, with cardiac imaging and documentation leading the charge[2]. That convergence of hardware growth and software integration is creating asymmetric upside for companies building the infrastructure layer: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), GE HealthCare Technologies (NASDAQ: GEHC), Medtronic (NYSE: MDT), Intuitive Surgical (NASDAQ: ISRG), and Johnson & Johnson (NYSE: JNJ).

Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content Story continues below This advertisement has not loaded yet, but your article continues below. Article content

The numbers tell a clear story. Analysts project remote cardiac monitoring will hit $12 billion by 2034, growing at an 11.3% compound annual rate as hospitals push patient surveillance beyond traditional walls[3]. The minimally invasive surgery market is expanding even faster, at a 16.05% CAGR through 2034, driven by systemic demand for shorter hospital stays and faster patient recovery[4]. Institutions are positioning now; the window for retail is still open.

Article contentTop Stories

Get the latest headlines, breaking news and columns.

By signing up you consent to receive the above newsletter from Postmedia Network Inc.

Thanks for signing up!

A welcome email is on its way. If you don't see it, please check your junk folder.

The next issue of Top Stories will soon be in your inbox.

Interested in more newsletters? Browse here.

Article content

VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just locked in a new healthcare partnership in Central America. The Toronto-based medtech company announced a collaboration with the Health Division of the Montecristo Group to roll out its AI-powered cardiac imaging platform across Costa Rica’s public and private hospital networks.

Article content

The technology at the centre of the deal is VentriPoint’s VMS+™ system. It takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to a cardiac MRI, but without the million-dollar machine or the months-long wait list. Under the collaboration, VentriPoint and Montecristo will work on remote screening for congenital and structural heart disease, integration of VMS+™ into clinical research programs, and wider deployment across Costa Rica’s medical system. The Metropolitano Research Institute, housed within Montecristo’s Hospital Metropolitano, will lead the clinical work on the ground.

Article content Story continues below This advertisement has not loaded yet, but your article continues below. Article content

It’s worth noting that Montecristo’s Hospital Metropolitano network also has an existing relationship with Sanford Health, one of the largest healthcare systems in the United States and a major provider of care to rural America. Sanford holds a minority equity stake in Montecristo’s holding company under an agreement focused on sharing best practices, training, and operational expertise.

Article content

“We are excited to collaborate with the Health Division of the Montecristo Group to enable the adoption of VMS+™ technology in Costa Rica,” said Hugh MacNaught, CEO of VentriPoint. “Their strong healthcare network, commitment to affordable high-quality care, and passion for innovation make them an ideal partner as we work to expand access to advanced cardiac diagnostics and support clinical research opportunities in central America.”

Article content

Costa Rica is the latest addition to a footprint that has been expanding steadily, that builds upon the hub-and-spoke model VPT is developing in cardiac care. VentriPoint
recently partnered with First Light Health, an Indigenous-owned medical services company, to deliver AI-powered cardiac diagnostics to Indigenous and remote communities across Canada through a hub-and-spoke model. Local providers capture ultrasound scans on-site while specialists at a central hub handle interpretation remotely. That program covers British Columbia, Yukon, Alberta, Manitoba, and New Brunswick, building on an earlier partnership with the Nisga̱‘a Valley Health Authority in northern BC. South of the border, the company also signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California’s Sacramento and San Francisco regions.